Utang jangka cendhak perusahaan: Harvard Bioscience, Inc. (HBIO)

Harvard Bioscience (HBIO) short-term liabilities reflect the impact of management's strategy to refresh the product line in favor of profitable automation systems. This trend is driven by scaling the offering of organoid analysis tools to increase B2B revenues. The 0.00 level captures the current state of obligations, which are being adjusted through factory optimization and high demand for electroporation equipment.

HBIO (Harvard Bioscience) riwayat Utang jangka cendhak perusahaan saka 04.07.2022 nganti 28.10.2026

Ringkesan rincian data analitis Harvard Bioscience Inc. (HBIO)

- rega lan prakiraan konsensus rega:

Rega saham Harvard Bioscience, Inc.|HBIO - Target median analis

- data kapitalisasi pasar:

Kapitalisasi pasar Harvard Bioscience, Inc.|HBIO - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Nilai Buku saben Saham Harvard Bioscience|HBIO - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku harvardbioscience.com|HBIO - Aset Agregat Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas Harvard Bioscience|HBIO - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Harvard Bioscience|HBIO - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Harvard Bioscience, Inc.|HBIO - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Harvard Bioscience

Pambiji fundamental perusahaan:Harvard Bioscience

Produk mawa merek Harvard Bioscience Inc.

This indicator reflects the total liabilities of Harvard Bioscience (HBIO) with a maturity horizon of up to twelve months, capturing the liquid burden on capital. By analyzing the volume of short-term liabilities, an investor assesses the company's ability to finance the delivery of high-precision bioanalysis systems without the risk of cash flow gaps, which determines the balance between financial stability and the pace of business scaling.

Analisis pesaing Harvard Bioscience